The cells would theoretically induce tissue recovery by contributing to a pool of cells within the intestine. The lining of the intestine has one of the highest cellular turnover rates in the body, with all cell types being renewed weekly from this pool of cells, located in an area of the intestine known as the crypt.
In the current study, the team used cell markers to identify a population of stem cells in human bone marrow with the highest potential to migrate to the intestine and thrive. The cells express high levels of a receptor (ephrin type B) that is involved in tissue repair and wound closure.
The cells also known to modulate inflammation were injected into fetal sheep at 55 to 62 days gestation. At 75 days post-gestation, the researchers found that most of the transplanted cells were positioned in the crypt area, replenishing the stem cells in the intestine.
"Previous studies in animals have shown that the transplantation of bone-marrow-derived cells can contribute to the regeneration of the gastrointestinal tract in IBD," said Almeida-Porada. "However, only small numbers of cells were successfully transplanted using this method. Our goal with the current study was to identify populations of cells that naturally migrate to the intestine and have the intrinsic ability to restore tissue health."
Almeida-Porada said that while the two studies show that the cells can migrate to and survive in a healthy intestine, the next step will be to determine whether they can survive in an inflamed intestine.
dalek_kelad • Mar 30, 2014 11:52 PM Flag
6users liked this postsusers disliked this posts0Reply
Research Supports Promise of Cell Therapy for Bowel Disease
From Wake Forest Baptist Medical Center:
WINSTON-SALEM, N.C. - Feb. 28, 2013 - Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).
Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions - ulcerative colitis and Crohn's disease - in which the intestines become red and swollen and develop ulcers, probably as the result of the body having an immune response to its own tissue.
While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. Because these therapies aren't always effective, scientists hope to use stem cells to develop an injectable cell therapy to treat IBD.
The research findings are reported online in the FASEB Journal (the journal of the Federation of American Societies for Experimental Biology) by senior researcher Graca Almeida-Porada, M.D., Ph.D., professor of regenerative medicine at Wake Forest Baptist's Institute for Regenerative Medicine, and colleagues.
The new research complements a 2012 report by Almeida-Porada's team that identified stem cells in cord blood that are involved in blood vessel formation and also have the ability to migrate to the intestine.
"We've identified two populations of human cells that migrate to the intestine - one involved in blood vessel formation and the other that can replenish intestinal cells and modulates inflammation," said Almeida-Porada. "Our hope is that a mixture of these cells could be used as an injectable therapy to treat I
I think I may be too analytical and I am not certain about certain rules regarding the FDA about changing a drug compounds during a trial? Furthermore, with stem cell technology being a fairly new and ever evolving science, what they knew in 2011 about the science and what they know now could be much different. For instance, if Athersys knew now that a certain protein could affect the efficacy of multistem would they be allowed to modify multistem to express that protein, or would the FDA restrict them from doing so during a trial?
Furthermore, according to the author I sited above...."..One platform, Random Activation of Gene Suppression (RAGE) "can be used to produce human cell lines EXPRESSING VIRTUALLY ANY PROTEIN ENCODED IN THE HUMAN GENOME, without requiring the cloning and isolation of individual genes."
Since independent research is pointing to the importance of expressing certain proteins within a cell to promote certain functions and interactions with other cells it seems that Athersys has its ducks in a row to be successful in the future. Now the question that remains is, is the future now.?
Still no answer to my email concerning "do the progenitor cells used in MultiStem express the Ephrin B receptor"? Which IMO could be very important in pertaining to the UC trials and MultiStems ability to promote cell regeneration within the intestinal tract. I am no scientist by any means. I just do an awful lot of reading and try to connect the dots pertaining to various research by any related studies. Do your own DD and share.
Certain proteins (receptors) within the stem cells enable them to adhere to other cells throughout the body. Do progenitor cells (MAPC) and MSC cells share the same proteins. That is the key. JMO.
The Key is to direct the stem cells to the part of the body where they are needed and Athersys is working on the answer. As regenerative Medicines techniques evolve Athersys Rage technology will be on the forefront. AJMO.
"Athersys, Inc. Has Blockbuster Potential
Mar. 27, 2013 4:56 PM ET | 14 comments | About: ATHX
Disclosure: I am long ATHX. (More...)
Athersys, Inc. (ATHX) is a small cap biotech stock that appears to have significant potential. What is initially intriguing about Athersys is that it holds proprietary Cell-Based Biology Platforms that aids in expediting drug discovery. One platform, Random Activation of Gene Suppression (RAGE) "can be used to produce human cell lines expressing virtually any protein encoded in the human genome, without requiring the cloning and isolation of individual genes." The RAGE technology portfolio includes 11 issued U.S. patents, pending patents, and international patents. Their other platform, Genome-wide, Cell-based Knock-out (GECKO) is a compliment to RAGE in that GECKO is proprietary, genetic technology that leads to the rapid identification of gene function, directly linking the gene to its role in the cell's biology and acceleration the functional validation of human genes. One does not need to be a scientist to understand the importance and value of having platforms that expedite drug discovery."
Ask yourself this, just what is he going to talk about.? I think they got out of regenerative medicine in 2011, with one exception, us. So, that being said, just what are Pfizers'
Successes? It would seem to me that he would have to at least mention MultiStem. But, you are right to release trial data Gil would also have to be present. I am certainly going to be interested in what he has to say.
Can't find the RNAi article that lead me to believe that. Perhaps I had them confused with someone else.
They just had a RNAi trial, which was involved in gene therapy ( associated with stem cells- I'm not certain) that was halted. Perhaps the " error along the path" they are referring to, sure hope it isn't us.
If you have an IRA through an online broker you can day trade.
If you have a 401K, you most likely cannot. The one I had with SAIC required me to have 50% of my funds in SAIC and the rest in a large selection of various mutual funds of my choice. I was able to change those ( although I don't remember if there was a limit) but it did help me in the crash of 2008 since I moved 1/2 my portfolio in some international mutual funds.
Day 2 - Thursday, April 24, 2014
PLENARY KEYNOTE PRESENTATION
8:00 Clinical Trials, Successes and Error Along the Path to Cell Therapy Products
Vice President, Regenerative Medicine
Full Definition of PLENARY 1 : complete in every respect : absolute , unqualified 2 : fully attended or constituted by all entitled to be present